Asarfi Hospital

Why is Asarfi Hospital Ltd falling/rising?

As of 09-Aug, Asarfi Hospital Ltd's stock price is at 221.85, reflecting a 5.49% increase. The stock has shown strong performance with a year-to-date rise of 17.94% and a 72.31% increase over the past year, despite a decline in investor participation.

As of 09-Aug, Asarfi Hospital Ltd's stock price is rising, currently at 221.85, reflecting an increase of 11.55 or 5.49%. The stock has shown strong performance over various periods, with a year-to-date increase of 17.94% compared to a decline of 7.89% in the Sensex. Over the past year, the stock has surged by 72.31%, while the benchmark has decreased by 2.63%. <BR><BR>Today, the stock has outperformed its sector by 4.82% and has been on a positive trend, gaining for the last three days with a total return of 10.06% during this period. It reached an intraday high of Rs 223.85, marking a 6.44% increase. Furthermore, Asarfi Hospital is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward momentum.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 29.82% against the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that the current rise is supported by solid performance metrics and market conditions.

Which are the latest news on Asarfi Hospital?

Should I buy, sell or hold Asarfi Hospital Ltd?

Are Asarfi Hospital Ltd latest results good or bad?

Asarfi Hospital Ltd's latest results show mixed performance: while net profit increased 9.19% year-on-year, it fell 27.68% quarter-on-quarter, and revenue grew 28.89% year-on-year but slightly declined 1.87% from the previous quarter. The drop in profitability margins has raised concerns, leading to a negative market reaction.

Asarfi Hospital Ltd's latest results present a mixed picture. In the fourth quarter of FY26, the company reported a net profit of ₹3.92 crore, which is a significant decline of 27.68% compared to the previous quarter. However, on a year-on-year basis, net profit increased by 9.19%. <BR><BR>Revenue for the same quarter was ₹45.24 crore, reflecting a slight decrease of 1.87% from the previous quarter but a robust increase of 28.89% year-on-year. While the top-line growth is encouraging, the decline in profitability metrics raises concerns. The operating margin fell sharply to 17.06%, down from 21.93% in the previous quarter, and the PAT margin also decreased to 8.66%, down from 11.76%. <BR><BR>Overall, while the revenue growth year-on-year is positive, the sequential decline in both net profit and operating margins indicates operational challenges that the company needs to address. This has led to a negative market reaction, with the stock experiencing a significant drop in value following the results. Investors may want to consider these factors carefully when evaluating the company's performance.

When is the next results date for Asarfi Hospital Ltd?

The next results date for Asarfi Hospital Ltd is 07 August 2026.

The next results date for Asarfi Hospital Ltd is scheduled for 07 August 2026.

What does Asarfi Hospital do?

Asarfi Hospital Ltd is a micro-cap company in the hospital industry, incorporated in 2005 and converted to a public limited company in 2012. As of March 2026, it reported net sales of 45 Cr and a net profit of 4 Cr, with a market cap of INR 427 Cr.

Overview: <BR>Asarfi Hospital Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Asarfi Hospital Limited was originally incorporated as a Private Limited Company on October 4, 2005, under the name "Asarfi Hospital Private Limited." The company later converted its status to Public Limited and changed its name to "Asarfi Hospital Limited" on February 08, 2012. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 45 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 4 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 427 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.46 <BR>Return on Equity: 17.06% <BR>Price to Book: 4.39 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

How big is Asarfi Hospital?

As of 10th June, Asarfi Hospital Ltd has a market capitalization of 427.00 Cr, with recent net sales of 171.91 Cr and a net profit of 16.66 Cr over the last four quarters. Shareholder's funds are 80.98 Cr, and total assets amount to 163.89 Cr as of March 2025.

As of 10th June, <BR><BR>Market Cap: Asarfi Hospital Ltd has a market capitalization of 427.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 171.91 Cr, while the sum of Net Profit for the same period is 16.66 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 80.98 Cr, and Total Assets amount to 163.89 Cr.

Who are in the management team of Asarfi Hospital?

The management team of Asarfi Hospital includes Udai Pratap Singh (Managing Director), Madhuri Singh (Executive Director), Sukanti Kumar Das (Director), Amit Kumar Barnwal (Independent Director), Rajkumari Sharma (Independent Director), and Seepika Gupta (Company Secretary & Compliance Officer).

The management team of Asarfi Hospital includes the following individuals:<BR><BR>1. **Udai Pratap Singh** - Managing Director<BR>2. **Madhuri Singh** - Executive Director<BR>3. **Sukanti Kumar Das** - Director<BR>4. **Amit Kumar Barnwal** - Independent Director<BR>5. **Rajkumari Sharma** - Independent Director<BR>6. **Seepika Gupta** - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about Asarfi Hospital or its operations, feel free to ask!

Who are the peers of the Asarfi Hospital?

Asarfi Hospital's peers include Shalby, GPT Healthcare, Lotus Eye Hospital, Aashka Hospitals, Chandan Healthcare, Aprameya Engineering, Unihealth Hospital, and Vaidya Sane. In terms of performance, Asarfi Hospital has a 1-year return of 64.21%, with management risk rated average and growth rated average compared to its peers.

Peers: The peers of Asarfi Hospital are Shalby, GPT Healthcare, Lotus Eye Hospit, Aashka Hospitals, Chandan Healthca, Aprameya Enginee, Unihealth Hosp, and Vaidya Sane.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Average management risk is found at Shalby, Chandan Healthca, Unihealth Hosp, Asarfi Hospital, and Vaidya Sane, and Below Average management risk is noted at Lotus Eye Hospit and Aashka Hospitals. Growth is rated as Excellent for Chandan Healthca and Average for Asarfi Hospital, while Below Average growth is seen at Shalby, GPT Healthcare, Lotus Eye Hospit, Aashka Hospitals, and Aprameya Enginee. Capital Structure is rated as Excellent for GPT Healthcare and Unihealth Hosp, Good for Shalby, Asarfi Hospital, Chandan Healthca, Aprameya Enginee, and Vaidya Sane, and Average for Aashka Hospitals, while Lotus Eye Hospit has a Good rating.<BR><BR>Return Snapshot: Asarfi Hospital has a 1-year return of 64.21%, which is higher than the peer with the highest return, Lotus Eye Hospit at 66.04%, and the peer with the lowest return, Aashka Hospitals at -24.05%. Additionally, Chandan Healthca, Aprameya Enginee, and Unihealth Hosp have a six-month return of 0.00%.

Is Asarfi Hospital overvalued or undervalued?

As of November 14, 2025, Asarfi Hospital is considered overvalued with a PE ratio of 31.38 and an EV to EBITDA of 16.34, despite strong stock performance, indicating it may not be an attractive investment compared to peers like Apollo Hospitals and Max Healthcare.

As of 14 November 2025, Asarfi Hospital's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.38, an EV to EBITDA of 16.34, and a PEG ratio of 0.20, which suggests growth potential relative to its valuation. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE ratio of 63.77 and an EV to EBITDA of 33.53, while Max Healthcare is marked as very expensive with a PE of 89.07. Despite the recent strong stock performance, with a year-to-date return of 75.1% compared to the Sensex's 8.22%, the elevated valuation metrics indicate that Asarfi Hospital may not present an attractive investment opportunity at current levels.

How has been the historical performance of Asarfi Hospital?

Asarfi Hospital experienced significant growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 120.57 Cr and profit after tax increasing to 10.58 Cr. However, cash flow from operating activities turned negative, indicating challenges in cash management despite strong revenue performance.

Answer:<BR>The historical performance of Asarfi Hospital shows significant growth from the previous year, with net sales increasing from 84.40 Cr in Mar'24 to 120.57 Cr in Mar'25. Total operating income mirrored this growth, rising to 120.57 Cr from 84.40 Cr. The total expenditure also increased, from 68.35 Cr to 97.01 Cr, primarily driven by higher raw material costs and other expenses. Operating profit (PBDIT) rose to 31.08 Cr from 17.72 Cr, while profit before tax improved from 6.24 Cr to 14.31 Cr. Consequently, profit after tax saw a substantial increase from 4.16 Cr to 10.58 Cr, resulting in an earnings per share (EPS) growth from 2.11 to 5.38. <BR><BR>In terms of balance sheet performance, shareholder's funds increased to 80.98 Cr from 70.41 Cr, and total liabilities rose to 163.89 Cr from 154.09 Cr. Long-term borrowings also increased significantly from 17.45 Cr to 33.83 Cr. Current assets improved to 58.48 Cr from 45.60 Cr, with notable increases in sundry debtors and inventories. However, cash flow from operating activities turned negative, dropping from 26.00 Cr to -4.00 Cr, while cash flow from financing activities decreased from 36.00 Cr to 12.00 Cr. Overall, Asarfi Hospital demonstrated strong revenue and profit growth, despite challenges in cash flow management.

Who are the top shareholders of the Asarfi Hospital?

The top shareholders of Asarfi Hospital include Harendra Singh with 18.78%, followed by public shareholder Gopal Singh at 2.4%. Individual investors collectively own 30.86% of the shares, with no pledged promoter holdings or involvement from mutual funds or foreign institutional investors.

The top shareholders of Asarfi Hospital primarily consist of the promoters, with Harendra Singh holding the largest stake at 18.78%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors involved. The highest public shareholder is Gopal Singh, who holds 2.4%. Additionally, individual investors collectively own 30.86% of the shares.

What is the technical trend for Asarfi Hospital?

As of May 19, 2025, Asarfi Hospital's technical trend is bullish, supported by a positive MACD and moving averages, although the weekly RSI indicates some potential weakness in momentum.

As of 19 May 2025, the technical trend for Asarfi Hospital has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate bullish momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the strength of the current trend. However, the weekly RSI is bearish, suggesting some potential weakness in momentum. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish MACD and moving averages.

Has Asarfi Hospital declared dividend?

No Dividend History Available